Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab withdrawal study for flare prevention in systemic juvenile idiopathic arthritis
NL-OMON35648Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Jan 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of canakinumab in systemic juvenile idiopathic arthritis (SJIA) (3 arms), sponsored by Novartis. Primary endpoints: Proportion of patients able to taper steroids per protocol in Part I and Time to flare in Part II. Started Jan 2010; status: active, not recruiting.
02
Drugs
canakinumab
03
Conditions
systemic juvenile idiopathic arthritis (SJIA)
Beyond the preview
Go deeper on NL-OMON35648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35648.